Poster zum Thema "Human Health Insights (Neurobiology, Cardiovascular, Liver, Kidney etc.)"

Zurück
  • P-III-0999
Acetylome mapping of tibialis anterior muscle from mdx mice upon pharmacological Sirtuin1 activation
  • P-III-1000
Exploring protein translation dynamics in autism spectrum disorder-associated mutations
  • P-III-1001
Proteomic analysis of cerebral microvascular endothelial cells under physiological normoxia and hyperoxia: implications for drug discovery
  • P-III-1002
Analysis of mouse plasma proteome reveals systemic effects of Bothrops jararaca snake envenomation
  • P-III-1003
Systemic changes in adults living with a fontan circulation – insights from 3000 plasma proteins
  • P-III-1004
Health and aging trajectories of human lung proteome: senescence, fibrosis, and aging signatures across lifespan in Naïve tissues and explant models
  • P-III-1005
Characterization and pathophysiological contribution of the proteome redox status in pseudomyxoma peritonei
  • P-III-1006
Elevated Markers of ECM Reorganization, Fibrosis, and Inflammation Uncovered in Accelerated Aging and Renal Dysfunction of Kidney Cortex and Medulla in Non-Human Primates Exposed to Ionizing Radiation
  • P-III-1007
The NAA10-related neurodevelopmental syndrome: proteomic insights from patient-derived neuronal iPSCs
  • P-III-1008
Exploring proteoform biomarkers to explain variability in pre-clinical cardiovascular disease risk among male and female young adults with high exposure to adverse childhood experiences
  • P-III-1009
Proteomic analysis of extracellular matrix produced by pericyte-like cells isolated from human glioblastomas
  • P-III-1010
Label-free proteomic analysis of P7C3-mediated protection in a rat model of Alzheimer's disease
  • P-III-1011
Extracellular LGALS3BP: a potential contributor in glioma progression and can serve as biomarker for early diagnosis
  • P-III-1012
The identification and mechanism exploration of GDF15 proteoforms in aging
  • P-III-1013
Sleep deprivation disrupts energy and lipid dynamics via the brain-brown adipose axis
  • P-III-1014
Proteomics into pathological mechanisms of Chronic Progressive External Ophthalmoplegia (CPEO): implications of the pathogenic variability
  • P-III-1015
Psychedelic-induced proteome changes in rodent brain regions
  • P-III-1016
FACS-Proteomics strategy toward extracellular vesicles single-phenotype characterization in biological fluids: insights into Leukocyte-derived EVs protein cargo and immunity
  • P-III-1017
Proteolytic signatures of coagulation identified and monitored by plasma peptidomics
  • P-III-1018
Spatial lipidomics via High Resolution MALDI-MSI highlights a cerebellum-specific molecular signature in the Marinesco-Sjogren mouse model
  • P-III-1019
Toward precision serology: resolving human polyclonal antibody repertoires with proteomics
  • P-III-1020
Proteomic characterization of acquired PARP inhibitor resistance in high-grade serous ovarian cancer
  • P-III-1021
Unraveling the proteomic and phosphoproteomics early events molecular effectors and signaling pathways of the Anti-CD19 CAR-T cell therapy
  • P-III-1022
Ultrasensitive profiling of > 300 plasma proteins for predicting biological age
  • P-III-1023
Investigation of Parkinson's disease heterogeneity and driving factors based on DIA proteomics analysis of patient PBMCs
  • P-III-1024
Amelioration of fibrosis in vitro through downregulation of TRPA1 channel
  • P-III-1025
Unbiased complexome profiling and global proteomics analysis reveals mitochondrial and intercalated disk alterations in presymptomatic R14Δ/+-PLN mice hearts
  • P-III-1026
Early candidate urine Biomarkers for detecting Alzheimer's disease before Amyloid-β Plaque deposition in an APP (swe)/PSEN1dE9 transgenic mouse model
  • P-III-1027
Preserved phosphorylation of mitochondrial creatine kinase 2 (CKMT2) confers cardioprotection against hypoxia/reoxygenation injury
  • P-III-1028
Salivary biomarkers in dementia
  • P-III-1029
Unraveling the proteome of human embryo peri-implantation development
  • P-III-1030
Use of proteomics to develop a novel diagnostic approach in pseudomyxoma peritonei
  • P-III-1031
Understanding the impact of genetic variants on Alzheimer's disease with mass spectrometry proteogenomics
  • P-III-1032
Characterisation of the cardiac function of alternative splicing-derived isoforms of synaptopodin 2-like protein (CHAP)
  • P-III-1033
Towards precision proteomics in the pathology of focal segmental glomerulosclerosis
  • P-III-1034
Cross-Omics Analysis of Proteome, Metabolome, and Transcriptome Dynamics during Peritoneal Dialysis
  • P-III-1035
Microsampling in a clinical setting enables stratification of heart failure patients
  • P-III-1036
Investigating the cardioprotective effects of SGLT-2 inhibitors
  • P-III-1037
Multi-omics analysis reveals phenotypic changes and energetic remodeling of VSMCs under Ang II treatment
  • P-III-1038
Revealing molecular subtypes and pathways in large vessel Occlusion stroke: a comprehensive quantitative proteomic analysis
  • P-III-1039
Targeted MS screen to characterize the complete human protein tyrosine phosphatase repertoire in liver metabolic diseases
  • P-III-1040
Proteome changes in lung cancer cell lines treated with grape extracts: a potential study for biomarkers
  • P-III-1041
Mass-spectrometry based proteomics reveals tissue specific metabolic perturbations in a mitochondrial disease mouse model
  • P-III-1042
Utilizing proteomic approaches to study the molecular effects of emerging plastic additives in human adipocytes
  • P-III-1043
Cereblon as potential biomarker for diabetic cardiomyopathy in type 2 diabetes-induced mice
  • P-III-1044
Peptidomics analysis of mouse tissues
  • P-III-1045
Proteomic workflows for deep phenotypic profiling of 3D organotypic liver models
  • P-III-1046
Profiling the proteome and phosphoproteome of testicular cancers (Germ Cell Tumors)
  • P-III-1047
Decoding Glycosylation Changes in the Prader-Willi Syndrome Mouse Brain
  • P-III-1048
Comprehensive plasma proteomics in heart failure patients: findings and future directions
  • P-III-1049
Evolution of proteomics of bioengineered human cardiac microtissues
  • P-III-1050
Chlordecone-induced hepatotoxicity and fibrosis are mediated by the proteasomal degradation of septins
  • P-III-1051
A high definition proteome of the human intervertebral disk: understanding lower back pain
  • P-III-1052
Isolation and Identification of mediators of heart failure in patients with cardiovascular disease
  • P-III-1053
Unveiling the distinct microproteome in cell lines and tissues derived from diverse stages of colorectal cancer
  • P-III-1054
Phosphorylation of MDH2 at S246 renders cardioprotection against hypoxia/reoxygenation injury
  • P-III-1055
Identification of potential urinary protein biomarkers in colorectal cancer: a pilot study using a proteomic approach
  • P-III-1056
Archaic NOVA1 alters FOXP2-expressing neurons upon lead exposure
  • P-III-1057
Quantitative analysis of the extracellular matrix in murine heart tissue
  • P-III-1058
Proteomic profiling of remodeling in hearts of an animal model of cardiometabolic syndrome
  • P-III-1059
Global proteomic profiling of a patient-derived 3D cyst model and reference tissue from polycystic kidney disease
  • P-III-1060
Global proteomics for routine assessment of in vitro 3D liver models used for drug development
  • P-III-1061
Changes in the cellular proteome and secretome in response to exposure of mouse renal mesangial cells to Bothrops jararaca snake venom
  • P-III-1062
Proteomic investigation of pathogenesis mechanisms and the role of ITIH4 in PM2.5-induced lung injury
  • P-III-1063
CRBN degrades Cav1.2α to regulate cardiac dysfunction
  • P-III-1064
Exercise mitigates cisplatin-induced neurotoxicity in murine hippocampus via attenuation of neuroinflammation and synaptic plasticity
  • P-III-1065
Proteomic mapping of different forms of amyotrophic lateral sclerosis
  • P-III-1066
Tau protein hyperphosphorylation during hibernation of golden hamsters: insights from a brain IP-MS study
  • P-III-1067
Do caloric restriction and aging affect mitochondrial protein oxidation in heart and brain tissue?
  • P-III-1068
Proteomic profiling of grey and white matter in the human brain using astral mass spectrometry
  • P-III-1069
Uncovering proteomic alterations in Parkinson's disease using patient-specific iPSC-derived brain cells
  • P-III-1070
Global protein turnover rates of primary Astrocytes in a mouse model of Parkinson's disease
  • P-III-1071
Proteomic insights into MrgD receptor deficiency: motor hyperactive- and compulsive-like phenotype, and synaptic dysfunction in the nigrostriatal pathway
  • P-III-1072
Proteomic basis for pancreatic acinar cell carcinoma and pancreatoblastoma as similar yet distinct entities and their contrast to pancreatic ductal adenocarcinoma
  • P-III-1074
Deep proteomic profiling of matched CSF and plasma samples for aging biomarker discovery beyond protein
  • P-III-1075
A Study on the expression profile of genes coding for secretory proteins using in vitro model of Alzheimer's disease
  • P-III-1077
Analysis of lysine metabolism in a rat model of type 2 diabetes reveals modulation of endocytosis and glucose metabolism
  • P-III-1078
Investigation of the influence of steroid receptor ligands on the neuronal proteome as a possible trigger for depression
  • P-III-1079
Characterization of brain α-synuclein in neurodegenerative diseases by high-resolution mass spectrometry
  • P-III-1080
The dysfunctional and immune reactive protein profile of ALS astrocytes rescued by FGF4 is abrogated by pro-inflammatory cytokine TNFa
  • P-III-1081
Characterization of an adipocytes: macrophages co-culture to model healthy and inflamed adipose tissue using proteomics
  • P-III-1082
The odd one out – Mass spectrometric detection of the ever-changing IgG4 landscape
  • P-III-1083
Eml1 depletion impairs the microtubule cytoskeleton and the binding affinity of its partners in cortical heterotopia